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STATEMENT OF TRANSLATIONAL RELEVANCE:  
Recurrent high-grade gliomas (HGGs) have a dismal prognosis and limited treatment options.  Loss of 
the urea cycle enzymes argininosuccinate synthetase 1 (ASS1) and/or argininosuccinate lyase (ASL), 
that synthesize arginine from citrulline, occurs in 70% of HGGs and sensitizes them to arginine 
deprivation by pegylated arginine deiminase (ADI-PEG20, pegargiminase) in pre-clinical models.  
Furthermore, ADI-PEG20 synergises with the antifolate agent pemetrexed to increase HGG cell death 
in vitro.  Translating these data, we show that ADI-PEG20 in combination with cisplatin and 
pemetrexed in heavily pre-treated patients with ASS1-deficient recurrent HGGs was well tolerated.  
Progression-free survival (PFS) and overall survival (OS) compared favourably with historical data in 
recurrent HGG.  Notably, a patient with primary isocitrate dehydrogenase (IDH) wildtype 
glioblastoma had a PFS of 20.8 months and OS of 24+ months, uncovering a potential role for 
quinine sulfate as an ADI-PEG20 re-sensitizer via autophagy inhibition.  Further ADI-PEG20 trials in 


























Background: Patients with recurrent high-grade gliomas (HGGs) are usually managed with alkylating 
chemotherapy +/- bevacizumab.  However, prognosis remains very poor.  Pre-clinically, we showed 
that HGGs are a target for arginine depletion with pegargiminase (ADI-PEG20) due to epimutations 
of argininosuccinate synthetase (ASS1) and/or argininosuccinate lyase (ASL).  Moreover, ADI-PEG20 
disrupts pyrimidine pools in ASS1-deficient HGGs, thereby impacting sensitivity to the antifolate, 
pemetrexed.   
Patients and methods: We expanded a Phase I trial of ADI-PEG20 with pemetrexed and cisplatin 
(ADIPEMCIS) to patients with ASS1-deficient recurrent HGGs (NCT02029690).  Patients were enrolled 
(01/16 – 06/17) to receive weekly ADI-PEG20 36 mg/m2 intramuscularly plus pemetrexed 500 mg/m2 
and cisplatin 75 mg/m2 intravenously once every three weeks for up to six cycles.  Patients with 
disease control were allowed ADI-PEG20 maintenance.  The primary endpoints were safety, 
tolerability and preliminary estimates of efficacy.  
Results: Ten ASS1-deficient heavily pre-treated patients were treated with ADIPEMCIS therapy. 
Treatment was well tolerated with the majority of adverse events being CTCAE v4.03 grade 1-2.  The 
best overall response was stable disease in 8 patients (80%).  Plasma arginine was suppressed 
significantly below baseline with a reciprocal increase in citrulline during the sampling period. The 
anti-ADI-PEG20 antibody titer rose during the first four weeks of treatment before reaching a 
plateau.  Median progression-free survival (PFS) was 5.2 months (95% CI 2.5-20.8) and overall 
survival (OS) was 6.3 months (95% CI 1.8-9.7).   
Conclusions: In this recurrent HGG study, ADIPEMCIS was well tolerated and compares favorably to 



















High-grade gliomas (HGGs) are usually treated with a combination of surgery and 
chemoradiotherapy in the first-line setting, but, despite these measures, recurrence is nearly 
universal (1).  At this point, treatment options are limited with no defined standard of care (2).  
Alkylating chemotherapy is most commonly used, but efficacy is poor with a progression-free 
survival (PFS) of around 1.5-3 months and an overall survival of 6-9 months (2).   New treatment 
options are urgently required. 
Arginine is a conditionally essential amino acid involved in the regulation of numerous cellular 
processes (3).  These include cell signaling, proliferation (by modulating polyamine and nucleotide 
synthesis), vasodilatation (via nitric oxide) and hormone synthesis (3).  Arginine also plays a crucial 
role in regulating the immune system in health and disease (4).    
Auxotrophy is the inability of an organism to synthesise an organic compound necessary for its 
growth (5).  Normal cells express the urea cycle enzymes argininosuccinate synthetase 1 (ASS1) and 
argininosuccinate lyase (ASL), which convert citrulline to arginine thereby providing an endogenous 
supply.  However, ASS1 is downregulated in many tumors, commonly through hypermethylation of 
the ASS1 promoter (6,7).  This leads to increased pyrimidine synthesis and consequent tumor 
proliferation, but renders the tumor dependent on exogenous arginine (6,8,9).  This can be exploited 
therapeutically using pegylated arginine deiminase (ADI-PEG20/pegargiminase) which catalyses the 
conversion of L-arginine to citrulline and an ammonium ion (10).  Importantly, low ASS1 expression is 
associated with a more aggressive clinical phenotype and a worse clinical outcome in several 
different cancer types (11-14). 
Initial clinical trials showed that ADI-PEG20 is well tolerated with injection site tenderness being the 
most commonly reported adverse event.  Allergic reactions have occurred, but anaphylaxis is rare 
(<1%).   The most common laboratory toxicities were mild (grade 1-2) asymptomatic elevations in 
various serum chemistry values, while neutropenia has been described infrequently (13,15,16).   
ADI-PEG20 has biological efficacy as a single agent in a range of tumors including melanoma, 
hepatocellular carcinoma and mesothelioma (13,15,16).  Furthermore, patients deficient in ASS1 
gained the most benefit from monotherapy (17).  In addition, pre-clinical studies of ADI-PEG20 
showed that arginine deprivation suppressed the folate-dependent enzymes thymidylate synthase 
(TS) and dihydrofolate reductase (DHFR) (12).  This leads to the potentiation of pemetrexed, an 
inhibitor of TS and DHFR, when combined with ADI-PEG20 (12).  Also, ADI-PEG20 potentiates the 
activity of cisplatin in melanoma cells by inhibiting synthesis of DNA repair enzymes that attempt to 
abrogate the effects of cisplatin (18).  Therefore, ADI-PEG20 enhances the activity of both folate 
inhibitors and platinum agents.  Furthermore, a Phase I trial combining ADI-PEG20, pemetrexed and 
cisplatin (ADIPEMCIS) has shown efficacy in patients with treatment-refractory ASS1-deficient 
mesothelioma or non-small cell lung cancer, thus validating this clinical approach (19).   
Pre-clinical findings have shown that 70% of HGG patient tissue samples were deficient in ASS1 (20).  
Arginine deprivation, either by exposure to arginine deiminase or arginase, inhibited the 
proliferation of patient-derived ASS1-deficient HGG cell lines and xenografts (20,21).  These pre-
clinical studies established that targeting arginine auxotrophy is a potential therapeutic strategy in 
HGG that would have the benefit of partially overcoming the limitations imposed by the blood-brain 
barrier by acting in the peripheral blood rather than the tumor (22).  This Phase I expansion cohort 
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assessed the safety and preliminary evidence for clinical activity using ADIPEMCIS in patients with 
recurrent or refractory HGG.  
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PATIENTS AND METHODS: 
Patients  
Eligible patients were 18 years of age or older with histologically confirmed HGG in which >50% of 
tumor cells did not express ASS1 as determined by immunohistochemistry (IHC; 0 or 1+ by ASS1 
immunohistochemistry 1:500; from Polaris Pharmaceuticals, Inc.) (7,13,19).  Archived tissue was 
used for ASS1 assessment where the initial diagnosis was HGG.  Patients who were initially 
diagnosed with a low-grade glioma were required to undergo a biopsy to confirm transformation to 
a HGG which was subsequently used for ASS1 assessment.  Patients must have failed first-line 
treatment with radiotherapy ± temozolomide (progressive disease and/or side-effects) and have 
evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (23).  Any steroid 
dose must have been stable for at least 5 days prior to the patient receiving the first ADI-PEG20 
dose.  Patients had an Eastern Co-operative Oncology Group (ECOG) performance status of 0-1 as 
well as adequate haematological, renal and hepatic function.  Exclusion criteria included 
radiotherapy or surgery within 4 weeks of first study treatment, ongoing toxic manifestations of 
previous treatments and significant concomitant or uncontrolled intercurrent illness.  Prior 
treatment with ADI-PEG20 was not allowed.   
The study was performed in accordance with good clinical practice and the European Union Clinical 
Trials Directive, with approval from Leeds East (Yorkshire and The Humber) ethical review board. All 
patients provided written informed consent. 
 
Study design and treatment 
This was an open-label, single arm, expansion cohort of a Phase I study conducted across two 
centers in the United Kingdom once the recommended Phase II dose (RP2D) of ADIPEMCIS had been 
determined by the dose escalation cohort (19).  The planned number of patients to be enrolled was 
ten.  The RP2D was weekly ADI-PEG20 36 mg/m2 intramuscularly (i.m.) plus pemetrexed 500 mg/m2 
and cisplatin 75 mg/m2 intravenously once every three weeks (19).  The initial dose of ADI-PEG20 
was given at least 48 hours in advance of the first dose of cytotoxic drugs.  To reduce pemetrexed 
toxicity, daily oral folic acid 400 µg and hydroxycobalamin 1000 µg i.m. every nine weeks were 
administered, starting at least seven days prior to first dose.  Oral dexamethasone 4 mg twice daily 
was given for three days with each cycle, starting the day before pemetrexed was due, if the patients 
were not already taking steroids or were on a lower dose.  Treatment continued for a maximum of 
six cycles (18 weeks) after which patients who had stable disease or better were eligible to continue 
on single-agent ADI-PEG20 until disease progression.   
 
Endpoints and assessment 
A data cut-off of 15 November 2018 was used.  The primary endpoints were safety, tolerability and 
preliminary estimates of efficacy by best overall response rate (ORR) as assessed by RECIST 1.1 (23).  
Secondary endpoints included PFS, OS, pharmacodynamics, immunogenicity.  Exploratory endpoints 
included analysis of ASS1/ASL epimutations.   
The safety and tolerability of ADIPEMCIS was assessed using National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03.   
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Baseline imaging by diffusion-weighted magnetic resonance imaging (DW-MRI) was undertaken 
within 21 days prior to the patient receiving the first ADI-PEG20 dose.  MRI scans were performed 
every six weeks during ADIPEMCIS dosing and after every eighth weekly dose of ADI-PEG20 during 
the maintenance phase. 
During combination treatment with ADIPEMCIS, blood samples were taken weekly for cycle 1 and 
then on days 1 and 15 for cycles 2-6 to analyse arginine and citrulline levels and for immunogenicity 
analyses, as described previously (13). 










Between January 2016 and June 2017, ten patients with HGG were enrolled from two centers in the 
United Kingdom (Table 1).  The age range was 43-63 years with a median age at enrolment of 51 
years.  Ninety percent of patients were male and 80% were Caucasian.  Twenty patients were 
screened with 18 (90%) being ASS1 deficient (Supplementary Fig. S1).  It was not possible to 
determine the ASS1 score for two patients who were therefore excluded.  The reasons for screen-
failure in the other eight patients were clinical deterioration (6, 60%) and withdrawal of consent (2, 
20%).   
For the ten treated patients, six had glioblastoma, one of which had transformed from a grade II 
astrocytoma (Table 2).  Three patients had anaplastic astrocytoma, one of which had transformed 
from a grade II astrocytoma.  One patient had an anaplastic oligodendroglioma (1p/19q codeleted) 
which had transformed from a grade II oligodendroglioma.   All patients with glioblastoma were 
isocitrate dehydrogenase (IDH) wildtype as assessed by R132H immunohistochemistry as was one 
patient with anaplastic astrocytoma.  Six patients had unmethylated O6-methylguanine-DNA 
methyltransferase (MGMT) promoters, three had methylated ones and it was not determined for 
one patient.  Ninety percent of patients had received two or more lines of systemic therapy prior to 
enrolment, including temozolomide, lomustine and procarbazine/lomustine/vincristine (PCV).  
 
Safety  
The majority (74%) of adverse events (AEs) were grade 1 or 2 (Table 3).  The commonest grade 1-2 
AEs seen in more than one patient related to at least one treatment agent were thrombocytopenia 
(5 patients, 50%), fatigue (3 patients, 30%), raised alanine aminotransferase (3 patients, 30%), 
nausea (2 patients, 20%) and dyspepsia (2 patients, 20%).  Eight patients (80%) experienced at least 
one grade 3-4 AE with neutropenia (4 patients, 40%) and thrombocytopenia (3 patients, 30%) being 
the most frequent.  There was one case of grade 3 neutropenic sepsis and one grade 3 rise in alanine 
aminotransferase level, both of which were treatment-related.  
Two patients did not have any follow-up scans after the first cycle of treatment: patient E chose to 
withdraw from the study; and patient C suffered a combination of adverse events, clinical 
progression and performance status deterioration.   
 
Pharmacodynamics 
Complete data were available for five patients over the 18-week period of blood sampling.  
Circulating plasma arginine levels fell rapidly upon commencing ADI-PEG20 and remained below 30% 
of baseline for the duration of the sampling period (Fig. 1a).  A reciprocal rise in citrulline as 
expected was also maintained throughout the sampling period.  Anti-ADI-PEG20 antibody titres rose 
during the first four weeks of ADI-PEG20 before plateauing at 10-2 for the remainder of the study 





The best response by RECIST 1.1 was stable disease seen in eight (80%) patients with two patients 
being non-evaluable due to lack of follow-up scans.  No complete or partial responses were seen.  
The median PFS was 5.2 months (95% confidence interval [CI] 2.6-20.8) and the median OS was 6.3 
months (95% CI 1.8-9.7).  Progression-free survival at six months (PFS6) was 20%.  Individual patient 
responses are summarised in Fig. 2 with Kaplan-Meier plots shown in Supplementary Figure S2.  
Notably, one patient with primary IDH wildtype, MGMT promoter unmethylated glioblastoma had a 
PFS of 20.8 months and remains alive currently (OS 24+ months).  Moreover, re-resection of his 
glioblastoma at disease progression continued to demonstrate ASS1 deficiency by IHC 
(Supplementary Fig. S1).  A retrospective analysis by Response Assessment in Neuro-Oncology 
(RANO) criteria was undertaken (24): two patients had a partial response as their best response to 
treatment, namely the two patients with the longest PFS of 20.8 and 9.3 months; one patient had 
stable disease; two patients had progressive disease; and five patients were non-evaluable owing to 
extensive necrosis.  Median PFS by RANO was 2.5 months (95% CI 0.0-9.2).   
 
ASS1 and ASL1 epimutations 
The promoter methylation status of ASS1 and ASL was determined for eight of the patients on 
treatment using archived tissue, except where a HGG had transformed from a low-grade glioma 
when new biopsy tissue was used (insufficient material for two patients).  There were no cases of 
ASL promoter methylation.  Three patients had at least one tumor sample that demonstrated 
methylation of ASS1 promoter and there were five patients with unmethylated tumors (Table 2).  
Two samples from the same tumor were tested for patient G.  Interestingly, one sample showed 







This is the first reported use of arginine deprivation therapy in combination with cisplatin and 
pemetrexed (ADIPEMCIS) in recurrent HGGs, a biomarker-led approach.  Patients enrolled in the trial 
had been heavily pre-treated with 90% having received at least two prior lines of chemotherapy.  
Unsurprisingly, the commonest AEs were related to bone marrow suppression, including grade 4 
neutropenia and thrombocytopenia, consistent with the chemotherapy.  However, no bleeding 
events occurred and there was only one episode of neutropenic sepsis, in line with the expected 
rate.  Overall, treatment was well tolerated.  
Arginine suppression was observed for the duration of ADIPEMCIS treatment together with a 
concomitant rise in citrulline.  The anti-ADI-PEG20 antibody titre rose to a peak of 10-2 by week four 
and then plateaued at this level for the remainder of treatment.  This is consistent with findings in 
thoracic tumor patients treated with ADIPEMCIS (19).   
Preliminary efficacy results showed PFS 5.2 months, OS 6.3 months and PFS6 20% by RECIST 1.1.  
These are in line with historical findings for recurrent HGG, albeit towards the lower end of the 
range.  This may be due to our population being more heavily pre-treated as 90% had received at 
least two prior lines of chemotherapy, compared to only one line in most studies (25-28).  In 
addition, ASS1 deficiency is associated with a worse prognosis in several different cancer types (11-
14).  However, given that our mixed population comprised grade III gliomas (better prognosis) and 
glioblastomas (worse prognosis), larger studies will be required to determine efficacy in these 
subtypes. 
One patient with primary glioblastoma who had poor prognostic features (IDH-wildtype, 
unmethylated MGMT promoter) had a PFS of 20.8 months and remains alive currently (OS 24+ 
months).  He had progressed after three cycles of adjuvant temozolomide and then again after two 
cycles (or 12 weeks) of PCV chemotherapy.  He commenced ADIPEMCIS in November 2016 and 
completed the first two cycles at 100% dose, but required dose reductions in cisplatin and 
pemetrexed for cycles three and four before they were stopped from cycle five onwards owing to 
recurrent grade 3-4 thrombocytopenia.  He continued on ADI-PEG20 monotherapy for a further 18 
months.  Radiologically, there had been a progressive increase in the enhancing component of the 
tumor from his first on-treatment MRI scan to 18% above baseline on the July 2017 scan (Fig. 3).  
However, arginine levels were suppressed in June 2018 after 16 months on ADI-PEG20 maintenance 
compared to baseline (data not shown) suggesting another mechanism causing disease progression.  
In July 2017, he was started on quinine sulfate 200 mg once daily by his physician for leg cramps.  
Subsequent scans showed that his tumor had stabilised before reducing in size which was sustained 
for a further twelve months and was associated with behavioural improvements.  Although only one 
patient with circumstantial evidence for an interaction, there is a pre-clinical basis for the effect.  
Autophagy is a known resistance mechanism of arginine deprivation therapy, and quinolone 
autophagy inhibitors have shown efficacy in pre-clinical tumor models treated with ADI-PEG20, 
including glioblastoma (20,29).  Indeed, recent studies confirm quinolone re-sensitization of glioma 
cell lines to targeted agents such as BRAF inhibitors, with clinical evidence of efficacy (30,31).  Thus, 
the potential synergy between ADI-PEG20 and autophagy inhibitors warrants further clinical 
investigation.  At disease progression, he underwent debulking surgery where the histology 
reconfirmed glioblastoma and molecular analysis showed no mutations in IDH1/2, although 
interestingly MGMT promoter methylation was now present at a low level (>0-5%) and may reflect 
prior treatment with cisplatin (32).  Intriguingly, his recurrent tumor on ADI-PEG20 monotherapy 
remained ASS1-deficient (Supplementary Fig. S1) implicating as yet unknown mechanisms of drug 
resistance to ADI-PEG20 that may include stromal provision of arginine or its precursors (9). 
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Platinum agents are an established treatment option in recurrent HGG (33,34).  However, to our 
knowledge, this is the first time pemetrexed has been trialled in this setting in more than one patient 
(clinic trial NCT00276783 recruited one patient only with HGG – J. Raizer, personal communication).  
This is despite pre-clinical evidence showing pemetrexed has activity in a xenograft model of 
glioblastoma and clinical studies showing that cisplatin/pemetrexed has efficacy in brain metastases 
(35-37).  Furthermore, pre-clinical data has shown that ADI-PEG20 suppresses the folate-dependent 
enzymes TS and DHFR in primary GBM cells (Supplementary Fig. S3a) and when combined with 
pemetrexed synergizes to decrease proliferation in an ASS1 negative glioma cell line, but not in an 
ASS1 positive cell line as has been seen previously in bladder cancer and malignant mesothelioma 
cell lines (Supplementary Fig. S3b) (12).   
This was an expansion cohort of the initial phase I TRAP trial which was conducted in thoracic 
tumors (19).  As such, RECIST 1.1 was used to evaluate progression-free survival (23).  This involves a 
unidirectional measurement of the target lesion, rather than a bidirectional one used by RANO (24).  
Despite these differences, the correlation between the two sets of criteria is usually good, although 
in our small sample set differences were seen (38).  Patient A had a PFS that was around two months 
shorter by RANO than RECIST 1.1 criteria.  In contrast, patient J had a sustained partial response by 
RANO but did have a progression event according to RECIST 1.1.  Future studies will employ RANO 
criteria exclusively.  Two patients had clinical progression, rather than radiological progression, 
which led to their data being censored by RECIST 1.1.  Patient A appeared to have disease 
progression on the July 2017 MRI scan with new left frontal enhancement (Fig. 3a).  However, this 
region was not measurable by RANO criteria owing to central necrosis and thin walls.  These findings 
highlight the well-documented issues with measuring PFS in HGGs.   
Ninety percent of patients screened were found to be deficient for ASS1 expression by 
immunohistochemistry using a less stringent threshold of >50% ASS1 loss than used in earlier studies 
that mandated >95-99% ASS1 loss (20).  Therefore, it is proposed that ASS1 expression status will 
not be required at study enrolment to minimise time to treatment, however subgroup analysis will 
be performed retrospectively.  In our small patient cohort, ASS1 promoter methylation occurred in 
only 30% of patients and did not correlate with treatment response in contrast to in vitro findings 
(20) (Table 2).  Heterogeneity was seen in one patient indicating that this may be an 
underrepresentation of the true rate.  Alternatively, methylation of ASS1 intron 1 may be a more 
important determinant than promoter methylation in clinical samples as shown in mesothelioma 
(11).  Also, ASS1-deficiency appears to be less important for medical benefit when ADI-PEG20 is 
combined with chemotherapy, as has been shown with gemcitabine and nab-paclitaxel in pancreatic 
cancer and with folinic acid, fluorouracil and oxaliplatin in hepatocellular carcinoma (39,40). 
In summary, the combination of ADI-PEG20, pemetrexed and cisplatin was well tolerated in patients 
with recurrent aggressive gliomas.  Preliminary estimates of efficacy were encouraging with the 
intriguing role of a quinolone-based autophagy inhibitor in combination with ADI-PEG20 needing 
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Characteristic No. of Patients 
Age, years 43-63 
Sex  
    Male 9 
    Female 1 
Diagnosis  
    Glioblastoma 6 
    Anaplastic astrocytoma 3 
    Anaplastic oligodendroglioma 1 
Performance status      
    0 0 
    1 10  
Prior systemic therapy  
    1 1 
    2 7 
    3 2 
ASS1 screening  
    Patients screened 20 
    Negative for ASS1 expression 18 (90%) 
    ASS1 expression not determine 2 (10%) 
    Patients ineligible / 
    rapid  disease progression / 
    unknown 
8  
    Patients enrolled 10 
 

















Toxicity Grade 1 or 2 Grade 3 Grade 4 
Thrombocytopenia* 4 3 1 
Fatigue 3   
ALT increased 2 1  
Nausea 2   
Neutropenia* 1 4 4 
Neutropenic sepsis  1  
Dehydration 1   
Headache 1   
Dysaesthesia 1   
Constipation 1   
Dyspepsia 1   
Dysgeusia 1   
Decreased appetite 1   
Purpura 1   
Convulsion 1   
Hypoalbuminaemia 1   
 
Table 2: Summary of treatment-related toxicities.  Number of patients reporting an adverse event 
related to at least one of the agents in treatment.  ALT, alanine aminotransferase.  *includes 



















Table 3: Individual patient tumoor characteristics. Unmeth, unmethylated; meth, methylated; ND, 
not determined; PFS, progression-free survival; OS, overall survival.  *concomitant and adjuvant 
temozolomide (Stupp protocol) counted as one line of treatment. 
  












1 Glioblastoma Wildtype Unmeth Unmeth 2 
2 Glioblastoma Wildtype Unmeth Unmeth 2 
3 Glioblastoma Wildtype Unmeth ND 2 
4 Glioblastoma Wildtype Meth Unmeth 2 
5 Glioblastoma Wildtype Meth Unmeth 2 
6 Glioblastoma 
(transformed) 
Wildtype Unmeth Meth 3 
7 Anaplastic 
Astrocytoma 
Wildtype Unmeth Meth 1 
8 Anaplastic 
Astrocytoma 
















Figure 1: Pharmacodynamic and immunogenicity studies. (A) Median serum concentrations of both 
arginine and citrulline and (B) mean serum levels of anti–ADI-PEG20 antibodies in patients treated 
with pegylated arginine deiminase combined with pemetrexed and cisplatin are shown by week of 


































































































Figure 2: Survival data for individual patients.  (A) Progression free survival and (B) Overall survival.  
Grey bars, isocitrate dehydrogenase wildtype glioblastoma; Black bars, other high-grade gliomas.  
See Table 3 for further information about each patient.  NS, no scans on treatment; *censored, from 


































Figure 3: MRI scan images showing response to treatment in (A) Patient 1 and (B) Patient 10.  (A) 
Representative images and RECIST 1.1 measurements for Patient 1 pre (November 2016 and July 
2017) and post (November 2017, June 2018 and August 2018) starting quinine sulfate.  (B) 
Representative images for Patient 10 showing baseline (left) and partial response to treatment by 
RANO criteria.  Note, the best response by RECIST 1.1 in Patient 10 was stable disease. 
Nov 2016: 32.5 mm 
Baseline  
July 2017: 38.4 mm 
+18%  
Nov 2017: 34.1 mm 
+5%  
Jun 2018: 30.9 mm 
-5% (Nadir)  
Aug 2018: 37.7 mm 





























Supplementary Figure S1:  ASS1 immunohistochemistry.  Representative images of ASS1 staining in 
tissue from patients’ glioma, showing strong expression in endothelial and microglial cells, but 
negative/weak expression in the glioma cells.  Pre, before trial treatment started; Post, after 
completion of trial (re-resection done for progressive disease).  For experimental methods, please 
see Szlosarek et al., 2017 (16).  All images were taken at x400. 
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Supplementary Figure S3:  Effects of ADI-PEG20 on the folate pathway.  (A) Representative western 
blot showing the addition of ADI-PEG20 reduces the expression of thymidylate synthase (TS) and 
dihydrofolate reductase (DHFR) in ASS1 negative glioblastoma primary cell lines.  (B) Pemetrexed 
(PEM) and ADI-PEG 20 (ADI) synergize to reduce proliferation in ASS1 negative glioblastoma cell line 
(SNB19) but not in ASS1 positive glioma cell line (8MG).  Experiments were repeated in triplicate. 
**P<0.01, *****P<0.001.  For experimental methods, please see Syed et al., 2013 (20).  
ADI-PEG20 A 
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